Moreover, in vivo therapeutic delivery of miR‐520d‐3p mimic and EphA2 siRNA induced potent synergy, resulting in substantial inhibition of tumor growth when compared with individual treatments in ovarian cancer tumor xenograft models (Nishimura et al., 2013). This evidence concerns the gene EPHA2 and ovarian carcinoma.